Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... MISSISSAUGA, Ontario, June 14, 2011 Theramed Corporation ... jetty™ at the 67th Clinical Meeting of the Society ... developed medical devices are to be used to advance ... Both medical device products have been approved for sale ...
... the 2011 Society of Gastroenterology Nurses and Associates (SGNA) ... PA) presented the results of a study evaluating the ... organic soils remaining in flexible endoscopes after cleaning. ... (Healthmark Industries Company, Inc., Fraser, Michigan) is to test ...
Cached Medicine Technology:Theramed Corporation to Launch Glenveigh Products, ebb™ and jetty™ at the Society of Obstetricians and Gynecologists of Canada 2Flexible Endoscope Manufacturer Determines Test Suitable for Evaluating Cleanliness of Flexible Endoscopes 2
(Date:10/22/2014)... Ann Arbor, MI (PRWEB) October 22, 2014 ... Association of Schools of Allied Health Professions (ASAHP) Conference ... Isabel Founder and CEO will participate in a panel ... Training and Practice. , Isabel Healthcare provides a diagnostic ... assist in improving the diagnosis skills of students and ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Calif., Feb. 27 Celebrities and Hollywood elite ... line - CellCeuticals(R) ... Hills plastic surgeon Dr. Garth Fisher and beauty ... at Social Hollywood located in the heart of ...
... Feb. 27 At a time when more and ... volunteer opportunities has,spiked. To encourage people to get involved ... 1.2 million men and,women members, has announced the "Moose ... the first time in its 121-year history, the Moose ...
... that exact in-flight medical emergency numbers hard to find , , ... the medical emergencies that occur on airplane flights involve fainting, ... lack of good data on such cases makes it hard ... , Researchers requested in-flight emergency data from 32 European airlines, ...
... shares poetry author,s two-year period of severe depressionBROOKLYN, N.Y., ... Arthur F. Temple kept a journal, in which the ... had become intolerable, and the result is this fascinating ... ).In nearly 100 poems, Temple shares his heartfelt feelings ...
... WASHINGTON, Feb. 27 The following was released today by Communion and Liberation: D ... 8 p.m. P L A C E: Gowan Hall ( Nursing-Biology ... University of America , 620 Michigan Avenue ... 20064 E V E N T: A Different Way of Facing H.I.V. ...
... CHADDS FORD, Pa., Feb. 27 Endo Pharmaceuticals (Nasdaq: ... licensed from Grunenthal the exclusive rights to develop and ... and Canada. Axomadol is a patented new chemical entity ... for the treatment of moderate to moderately severe chronic ...
Cached Medicine News:Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 2Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 3Health News:Moose Launch Organization's Own 'Economic Stimulus Plan' 2Health News:Fainting Most Common Medical Crisis on Planes 2Health News:Fainting Most Common Medical Crisis on Planes 3Health News:Fainting Most Common Medical Crisis on Planes 4Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Licenses Novel Pain Therapy from Grunenthal 2Health News:Endo Licenses Novel Pain Therapy from Grunenthal 3Health News:Endo Licenses Novel Pain Therapy from Grunenthal 4
... Control is a human ... provides the laboratory with ... for lipids analysis. It ... in levels optimized for ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Medicine Products: